NATCOPHARM

Natco Pharma Share PriceNatco Pharma

₹780.25
6.2 (0.8%)
As on 30 November, 2023 | 08:59 BSE: 524816 NSE: NATCOPHARMISIN: INE987B01026

Natco Pharma Performance

Day Range

  • Low 0.00
  • High 0.00
₹ 780.25

52 Week Range

  • Low 0.00
  • High 928.00
₹ 780.25
  • Open Price788.80
  • Previous Close780.25
  • Volume43

Start SIP in Natco Pharma

Start SIP

Natco Pharma Share Price

  • Over 1 Month -3.15%
  • Over 3 Month -12.82%
  • Over 6 Month 23.24%
  • Over 1 Year 38.61%

Natco Pharma Key Statistics

P/E Ratio 12.4
PEG Ratio 0.1
Market Cap Cr 13,975
Price to Book Ratio 2.9
EPS 34.7
Dividend 1.2
Relative Strength Index 47.64
Money Flow Index 48.57
MACD Signal -11.12
Average True Range 25.87

Natco Pharma Investment Rating

  • Master Rating:
  • Natco Pharma has an operating revenue of Rs. 3,562.30 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 32% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 15% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 48 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Natco Pharma Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 9311,048781413351806514
Operating Expenses Qtr Cr 488545454346281426552
Operating Profit Qtr Cr 4425043286870379-38
Depreciation Qtr Cr 40403838383736
Interest Qtr Cr 3313234
Tax Qtr Cr 6470528965-6
Net Profit Qtr Cr 3604052543738308-61
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 2,4371,862
Operating Expenses Annual Cr 1,5061,555
Operating Profit Annual in Cr 845213
Depreciation Cr 151138
Interest Annual Cr 913
Tax Annual Cr 13417
Net Profit Annual Cr 637139
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 78458
Cash from Investing Activity Annual Cr -437-93
Cash from Financing Annual Activity Cr -34736
Net Cash Flow Annual Cr 11
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 4,7024,192
Fixed Assets Annual Cr 2,2972,303
Total Non Current Assets Annual Cr 2,8932,800
Total Current Assets Annual Cr 2,4952,178
Total Assets Annual Cr 5,3884,978
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 258230
ROE Annual % 143
ROCE Annual % 164
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 4017
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 1,0311,141898493432885597
Operating Expenses Qtr Cr 573613559387337489615
Operating Profit Qtr Cr 45852833910695395-19
Depreciation Qtr Cr 44444142424038
Interest Qtr Cr 4434447
Tax Qtr Cr 7180491914651
Net Profit Qtr Cr 3694202766257320-51
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 2,8122,044
Operating Expenses Annual Cr 1,7721,681
Operating Profit Annual in Cr 936264
Depreciation Cr 164143
Interest Annual Cr 1518
Tax Annual Cr 14732
Net Profit Annual Cr 715170
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 84947
Cash from Investing Activity Annual Cr -477-5
Cash from Financing Annual Activity Cr -36335
Net Cash Flow Annual Cr 976
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 4,8744,264
Fixed Assets Annual Cr 2,4362,391
Total Non Current Assets Annual Cr 2,6572,612
Total Current Assets Annual Cr 3,0002,497
Total Assets Annual Cr 5,6575,109
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 267234
ROE Annual % 154
ROCE Annual % 185
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 3819

Natco Pharma Technicals

EMA & SMA

Current Price
₹780.25
6.2 (0.8%)
pointer
  • Bullish Moving Average
  • ___
  • 7
  • Bearish Moving Average
  • ___
  • 9
  • 20 Day
  • ₹782.22
  • 50 Day
  • ₹798.69
  • 100 Day
  • ₹785.53
  • 200 Day
  • ₹742.26
  • 20 Day
  • ₹767.32
  • 50 Day
  • ₹814.64
  • 100 Day
  • ₹817.82
  • 200 Day
  • ₹703.77

Natco Pharma Resistance and Support

PIVOT
₹779.77
Resistance
First Resistance 787.43
Second Resistance 794.62
Third Resistance 802.28
RSI 47.64
MFI 48.57
MACD Single Line -11.12
MACD -6.87
Support
First Resistance 772.58
Second Resistance 764.92
Third Resistance 757.73

Natco Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 813,969 59,020,892 72.51
Week 564,320 34,367,103 60.9
1 Month 1,072,939 57,541,731 53.63
6 Month 813,974 42,228,952 51.88

Natco Pharma Result Highlights

Natco Pharma Synopsis

NSE-Medical-Diversified

Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2351.00 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2023. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.
Market Cap 13,975
Sales 3,173
Shares in Float 8.96
No of funds 269
Yield 1.22
Book Value 3.03
U/D Vol ratio 0.8
LTDebt / Equity
Alpha 0.14
Beta 0.28

Natco Pharma

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 49.71%49.76%48.84%48.82%
Mutual Funds 7.65%9.45%8.5%8.18%
Insurance Companies 6.34%5.57%6.42%6.18%
Foreign Portfolio Investors 12.82%11.03%11.91%11.73%
Financial Institutions/ Banks
Individual Investors 19.5%20.21%20.24%19.83%
Others 3.98%3.98%4.09%5.26%

Natco Pharma Management

Name Designation
Mr. V C Nannapaneni Managing Director
Mr. Rajeev Nannapaneni Director & CEO
Mr. T V Rao Independent Director
Mr. G S Murthy Chairman & Ind.Director
Mr. D G Prasad Independent Director
Dr. M U R Naidu Independent Director
Dr. Leela Digumarti Independent Director
Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
Dr. Linga Rao Donthineni Director & President (Tech. Affairs)
Mr. Pavan Bhat Director

Natco Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Natco Pharma Corporate Action

Date Purpose Remarks
2023-11-14 Quarterly Results & Interim Dividend
2023-08-09 Quarterly Results & Interim Dividend
2023-05-29 Audited Results
2023-03-08 Buy Back of shares
2023-02-09 Quarterly Results & Interim Dividend
Date Purpose Remarks
2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend
2023-02-21 INTERIM Rs.1.25 per share (62.5%) Third Interim Dividend
2022-11-22 INTERIM Re.0.75 per share (37.50%) Second Interim Dividend
2022-08-22 INTERIM Rs.3.50 per share(175%)Interim Dividend

Natco Pharma MF Shareholding

Name Amount(cr)
ICICI Prudential Value Discovery Fund Growth 32,494
Mirae Asset Emerging Bluechip Fund Growth 28,104
SBI Magnum Midcap Fund Regular Growth 13,202
ICICI Prudential India Opportunities Fund Regular Growth 12,448
Mirae Asset Midcap Fund Regular Growth 11,784

Natco Pharma FAQs

What is Share Price of Natco Pharma ?

Natco Pharma share price is ₹780 As on 30 November, 2023 | 08:45

What is the Market Cap of Natco Pharma ?

The Market Cap of Natco Pharma is ₹13975 Cr As on 30 November, 2023 | 08:45

What is the P/E ratio of Natco Pharma ?

The P/E ratio of Natco Pharma is 12.4 As on 30 November, 2023 | 08:45

What is the PB ratio of Natco Pharma ?

The PB ratio of Natco Pharma is 2.9 As on 30 November, 2023 | 08:45

Q2FY23